EPICEL Market Market Size, Forecast, and Drug Insight – 2032

Published Date : 2023
Pages : 30
Region : United States, Japan, EU4 & UK

Share:

Market Drug Insight

“EPICEL Market Market Size, Forecast, and Drug Insight – 2032” report provides comprehensive insights about EPICEL for Burns in the United States market. A detailed picture of the EPICEL for Burns in the United States for the study period 2019 –2032 is provided in this report along with a detailed description of the EPICEL for Burns. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPICEL market forecast analysis for Burns in the United States descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in Burns.

Drug Summary

EPICEL is a cultured epidermal autograft (CEA)—a skin graft grown from a patient’s skin. These grafts provide skin replacement for patients with deep dermal or full-thickness burns comprising a TBSA of greater than or equal to 30%. From two postage stamp-sized biopsies, Vericel can grow enough skin to cover the patient’s entire body. It may be used in conjunction with split-thickness autografts or alone in patients for whom split-thickness autografts may not be an option due to the severity and extent of their burns.

EPICEL is an aseptically processed wound dressing composed of the patient’s own (autologous) keratinocytes grown ex vivo in the presence of proliferation-arrested murine (mouse) fibroblasts. EPICEL consists of sheets of proliferative, autologous keratinocytes, ranging from 2 to 8 cell layers thick, and is referred to as a cultured epidermal autograft. Each graft of EPICEL is attached to a petrolatum gauze backing with titanium surgical clips and measures approximately 50 cm2 in the area.

Scope of the Report

The report provides insights into:

  • A comprehensive product overview including the EPICEL description, mechanism of action, dosage and administration, research and development activities in Burns.
  • Elaborated details on EPICEL regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the EPICEL research and development activities in Burns across the United States.
  • The report also covers the patents information with expiry timeline around EPICEL.
  • The report contains forecasted sales of for Burns till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Burns.
  • The report also features the SWOT analysis with analyst views for EPICEL in Burns.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPICEL Analytical Perspective by DelveInsight

  • In-depth EPICEL Market Assessment

This report provides a detailed market assessment of EPICEL for Burns in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

  • EPICEL Clinical Assessment

The report provides the clinical trials information of EPICEL for Burns covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

  • In the coming years, the market scenario for Burns is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPICEL dominance.
  • Other emerging products for Burns are expected to give tough market competition to EPICEL and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPICEL in Burns.
  • Our in-depth analysis of the forecasted sales data of EPICEL from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPICEL in Burns.

Key Questions

  • What is the product type, route of administration and mechanism of action of EPICEL?
  • What is the clinical trial status of the study related to EPICEL in Burns and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPICEL development?
  • What are the key designations that have been granted to EPICEL for Burns?
  • What is the forecasted market scenario of EPICEL for Burns?
  • What are the forecasted sales of EPICEL in the United States?
  • What are the other emerging products available and how are these giving competition to EPICEL for Burns?
  • Which are the late-stage emerging therapies under development for the treatment of Burns?

Tags:

  • EPICEL
  • EPICEL Marketed Drugs Overview
  • EPICEL Market Assessment
  • EPICEL API Manufacturers/ Active Pharmaceutical Ingredients Manufacturers